Panirid : Each film-coated tablet contains Paroxetine Hydrochloride Hemihydrate BP equivalent to Paroxetine 20 mg.
The efficacy of paroxetine in the treatment of major depressive disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, and posttraumatic stress disorder is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin. Studies demonstrated that paroxetine blocks the uptake of serotonin into human platelets. In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic, alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.
Paroxetine is indicated for Major Depressive Disorder, Obsessive Compulsive Disorder, Panic Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder and Posttraumatic Stress Disorder
Major Depressive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder and Posttraumatic Stress Disorder- Initial dose 20 mg/day, maximum up to 50 mg/day
Obsessive Compulsive Disorder and Panic Disorder- Initial dose 20 mg/day, Maintenance dose: 40 mg/day, Maximum dose: 60 mg/day
Most common adverse reactions include-somnolence, insomnia, agitation, tremor, anxiety, dizziness, constipation, nausea, diarrhea, dry mouth, flatulence etc. Other rare side-effects include- asthenia, abnormal ejaculation, sweating, impotence, decreased libido etc.
All patients being treated with paroxetine for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
Pregnancy: Pregnancy Category D.
Nursing mothers: Paroxetine is excreted in human milk. Caution should be exercised when paroxetine is administered to a nursing woman.
Safety and effectiveness in the pediatric population have not been established.
Use in elderly, renal and hepatic impaired patients
The recommended initial dose is 10 mg/day for elderly patients, and/or patients with severe renal or hepatic impairment. Dosage should not exceed 40 mg/day.